Verily Life Sciences LLC, Alphabet Inc’s life sciences division, has raised $700 million in funding, reported Reuters. The backers include Alphabet, Silver Lake and Temasek. The news wire noted that Verily had developed a COVID-19 test, “which was granted an emergency use authorization by the U.S. Food and Drug Administration in September.”
Source: Reuters
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.